EMA’s CHMP recommends revoking EU approval of TAVNEOS (avacopan) over Phase 3 ADVOCATE trial data handling concerns. CSL pledges continued support for ANCA-associated vasculitis patients during the transition.
Written By: Nalam Karthik, PharmD
Reviewed By: Pharmacally Editorial Team
The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended revoking the European Union (EU) marketing authorization for TAVNEOS (avacopan), an oral treatment for adults with severe, active granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA), the two major forms of ANCA-associated vasculitis (AAV).
The recommendation has been forwarded to the European Commission (EC), which is expected to issue a final legally binding decision shortly. If adopted, TAVNEOS will no longer be authorized in the EU or European Economic Area (EEA). Pending the decision, no new patients will begin treatment with the medicine, while patients already receiving TAVNEOS are advised to consult their treating physicians before making any treatment changes.
CHMP Review Triggered by ADVOCATE Trial Data Concerns
The recommendation follows an Article 20 non-pharmacovigilance referral procedure initiated after concerns emerged regarding data handling in the pivotal Phase 3 ADVOCATE trial, which supported the drug’s approval. The review was not prompted by newly identified safety signals but by questions surrounding the integrity of clinical trial data.
The decision marks a significant regulatory setback for TAVNEOS in Europe and underscores the importance of robust clinical data in supporting marketing authorizations.
About TAVNEOS and ANCA-Associated Vasculitis
TAVNEOS is a first-in-class oral complement C5a receptor 1 (C5aR1) inhibitor approved for use in combination with rituximab or cyclophosphamide in adults with severe, active GPA or MPA.
By selectively blocking the C5a receptor on neutrophils, avacopan reduces complement-mediated inflammation that drives vascular injury in ANCA-associated vasculitis while preserving other important immune functions.
ANCA-associated vasculitis is a rare, life-threatening autoimmune disease in which the immune system attacks small blood vessels, leading to inflammation and progressive organ damage, particularly in the kidneys and lungs. Although available therapies have improved outcomes, many patients continue to experience relapses and complications associated with long-term glucocorticoid treatment, leaving a substantial unmet medical need.
Commitment to the ANCA-Associated Vasculitis Community
CSL and Vifor Fresenius Medical Care Renal Pharma (VFMCRP) said patient care remains their highest priority throughout the regulatory process. The companies are working closely with regulatory authorities, healthcare professionals, and patient organizations to ensure patients receive appropriate guidance and support during the treatment transition.
They also reaffirmed their long-standing commitment to the ANCA-associated vasculitis community, stating they will continue providing medical information and updates while advancing innovative therapies for rare diseases. Patients currently receiving TAVNEOS are encouraged to discuss their ongoing treatment with their healthcare providers.
Clinical Implications
Dr. Bill Mezzanotte, Head of Research and Development at CSL, said the companies were disappointed by the CHMP recommendation but would fully respect and implement the regulatory outcome. He acknowledged the important role TAVNEOS has played for patients living with ANCA-associated vasculitis and emphasized the companies’ commitment to supporting patients and clinicians throughout the transition while continuing to invest in treatments for rare diseases.
Path Forward
TAVNEOS was originally developed by ChemoCentryx, which was acquired by Amgen in 2022. Amgen remains the New Drug Application (NDA) holder in the United States, while CSL commercializes the medicine outside the U.S. in selected markets under a licensing agreement with Vifor Fresenius Medical Care Renal Pharma.
The European Commission is expected to make the final decision on the CHMP recommendation in the coming weeks. If confirmed, TAVNEOS will lose its EU marketing authorization, bringing an end to its commercial availability across the region while patients transition to alternative treatment strategies under physician supervision.
What This Means for Patients
TAVNEOS provided a steroid-sparing treatment option for adults with ANCA-associated vasculitis, helping reduce disease-related inflammation while lowering glucocorticoid exposure. If the European Commission confirms the CHMP recommendation, patients in the EU may lose access to this targeted therapy and will need to discuss alternative treatment strategies with their healthcare providers.
Patients currently receiving TAVNEOS should consult their treating physicians before making any treatment changes. The decision also highlights the continued need for new targeted therapies that improve long-term outcomes for people living with this rare, life-threatening autoimmune disease.
Reference
CHMP recommends revoking marketing authorisation for TAVNEOS® (avacopan) in the European Union
About the Writer
Nalam Karthik (LinkedIn) is a healthcare writer and PharmD graduate with interests in pharmacovigilance, drug safety, clinical data analysis, and quality assurance. He is passionate about translating clinical and pharmaceutical knowledge into accessible healthcare content while staying engaged with advancements in drug development and patient safety initiatives.